Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $3.7B | $631M | $314M | $465M | 39.8% | 65.2% | -212.8% |
| 2024 | $2.2B | $-179M | $-278M | $-43M | -414.6% | 23.0% | -36.8% |
| 2023 | $1.8B | $-258M | $-440M | $42M | 199.5% | 76.2% | -61.1% |
| 2022 | $1.0B | $-927M | $-1.1B | $-613M | 714.9% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 3,713.94 |
| Operating Revenue | 3,713.94 |
| Cost Of Revenue | 681.87 |
| Gross Profit | 3,032.07 |
| Operating Expense | 2,530.49 |
| Research And Development | 1,319.78 |
| Selling General And Administration | 1,210.71 |
| Total Expenses | 3,212.36 |
| Operating Income | 501.58 |
| Total Operating Income As Reported | 501.58 |
| EBITDA | 631.44 |
| Normalized EBITDA | 676.22 |
| EBIT | 575.78 |
| Interest Income | 111.47 |
| Interest Expense | 252.63 |
| Net Interest Income | -141.16 |
| Other Non Operating Income Expenses | 7.51 |
| Other Income Expense | -37.27 |
| Interest Income Non Operating | 111.47 |
| Interest Expense Non Operating | 252.63 |
| Net Non Operating Interest Income Expense | -141.16 |
| Pretax Income | 323.15 |
| Tax Provision | 9.40 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | -1.30 |
| Net Income Continuous Operations | 313.75 |
| Net Income From Continuing And Discontinued Operation | 313.75 |
| Net Income From Continuing Operation Net Minority Interest | 313.75 |
| Net Income | 313.75 |
| Net Income Common Stockholders | 313.75 |
| Net Income Including Noncontrolling Interests | 313.75 |
| Normalized Income | 357.23 |
| Diluted NI Availto Com Stockholders | 313.75 |
| Basic Average Shares | 131 |
| Diluted Average Shares | 134.68 |
| Reconciled Depreciation | 55.66 |
| Reconciled Cost Of Revenue | 681.87 |
| Total Unusual Items | -44.78 |
| Total Unusual Items Excluding Goodwill | -44.78 |
| Special Income Charges | -42.47 |
| Other Special Charges | 42.47 |
| Gain On Sale Of Security | -2.31 |
| General And Administrative Expense | 1,210.71 |
| Other Gand A | 348.98 |
| Salaries And Wages | 668.30 |
| Rent Expense Supplemental | 193.44 |
| Rent And Landing Fees | 193.44 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc.this co. | ALNY | $40.5B | 129.21↑ premium | 51.37 | 39.8% | 61.62 |
| Cardinal Health, Inc. | CAH | $47.2B | 30.27 | -16.99 | -56.1% | 16.71 |
| IDEXX Laboratories, Inc. | IDXX | $44.5B | 42.05 | 27.75 | 66.0% | 30.06 |
| Humana Inc. | HUM | $42.0B | 35.35 | 2.38 | 6.7% | - |
| Becton, Dickinson and Company | BDX |
| 2021 |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $41.2B |
| 24.56 |
| 1.62 |
| 6.6% |
| 12.06 |
| Agilent Technologies, Inc. | A | $39.1B | 29.99 | 5.80 | 19.3% | 22.15 |
| Waters Corporation | WAT | $37.0B | 57.52 | 14.43 | 25.1% | 36.74 |
| Zoetis Inc. | ZTS | $33.3B | 12.47 | 10.01 | 80.2% | 9.90 |
| IQVIA Holdings Inc. | IQV | $31.2B | 22.93 | 4.80 | 20.9% | 13.04 |
| Peer Median | - | 30.13 | 5.30 | 20.1% | 16.71 | |